NYSE · Drug Manufacturers - Specialty & Generic · USD
Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited (TEVA) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TEVA Key Statistics
As of Sep 4, 2026Trading
- Open
- $36.40
- Previous Close
- $36.62
- Day's Range
- 36.13–36.93
- 52-Week Range
- 18.21–38.37
- Volume
- 7.40M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.87
Valuation
- Market Cap
- $42.37B
- P/E Ratio
- 60.60
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 11.84
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 0.67
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.45
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.60
Financials (FY)
- Revenue (FY)
- $17.26B+4.31%
- Net Income (FY)
- $1.41B
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 4.08%
- Shares Outstanding
- 1.17B
- 1-Year Return
- +96.75%
Dividend and dates
- Earnings Date
- November 4, 2026estimated
- Avg Volume
- 5.51M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
TEVA Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +16.50% |
| 2025 | +41.61% |
| 2024 | +111.11% |
| 2023 | +14.47% |
| 2022 | +13.86% |
| 2021 | −16.99% |
| 2020 | −1.53% |
| 2019 | −36.45% |
| 2018 | −18.63% |
| 2017 | −45.96% |
| 2016 (partial year) | −30.86% |
As of September 4, 2026.
TEVA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $17.26B | $1.41B | 8.2% |
| 2024 | $16.54B | −$1.64B | −9.9% |
| 2023 | $15.85B | −$559.00M | −3.5% |
| 2022 | $14.93B | −$2.45B | −16.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $17.26B | $8.94B | $3.95B | $1.41B | 8.2% |
| 2024 | $16.54B | $8.06B | $3.36B | −$1.64B | −9.9% |
| 2023 | $15.85B | $7.65B | $3.19B | −$559.00M | −3.5% |
| 2022 | $14.93B | $6.97B | $2.69B | −$2.45B | −16.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
TEVA Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 103 stocks| Metric | TEVA | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/E | 60.60 | 19.27 | 3.1x the median |
| P/S ratio | 2.45 | 2.30 | 7% above |
| Profit margin | 4.08% | −3.14% | 7.2 pts above |
Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - Slideshow
SeekingAlphaTeva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
YahooS&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
YahooUBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
BenzingaTEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
YahooTeva’s mAb shows benefit in celiac disease study
Yahoo
All 20 articles ↓Show fewer ↑
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
SeekingAlphaTeva Reports Significant Prevention Of Gluten-Induced Damage in New Study
YahooTeva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
YahooTeva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
YahooTeva Reports Significant Prevention Of Gluten-Induced Damage in New Study
BenzingaTeva claims success in celiac study; BioMarin, Ascendis settle patent dispute
YahooTeva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
BenzingaTeva Says Topline Results From Ongoing Phase 2a Study Of TEV ‘408 For Celiac Disease Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Prevention Of Gluten-induced Intestinal Damage Versus Placebo At Week 8
BenzingaTeva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
YahooTrump Announces Drug Pricing Deals with Teva, 8 Other Companies
YahooTeva And Trump Administration Commit To Lowering Select Medicaid Drug Costs
BenzingaBioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
BenzingaMajor Update: Amir Weiss At Teva Pharmaceutical Indus Exercises Options, Realizing $46K
BenzingaAurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$58.92B
HLNHaleon plc
$42.22B
ZTSZoetis Inc.
$31.33B
UTHRUnited Therapeutics Corporation
$20.91B
VTRSViatris Inc.
$19.39B
NBIXNeurocrine Biosciences, Inc.
$15.82B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B